$1.3B business unit addressing the worldwide problem of chronic pain. Member of senior staff of $7B Group reporting to Group President.• Turned around all 3 businesses growing revenue 11%, EBIT 18%, and EBIT margin 230bps in final year, exceeding revenue and EBIT in each quarter.• Created the structure and staffed 3 general manager-led businesses: 1) spinal cord stimulation and nerve ablation therapies, 2) implantable drug pump systems, 3) interventional spine (kyphoplasty, tumor ablation).• Led 2 acquisitions and multiple external investments/collaborations.• Closed pre-existing FDA Warning Letter and lifted distribution requirements under Consent Decree.• Won Medtronic-wide awards: Best Product Launch Revenue ($294M, 2019); Best Gross Margin Improvement (137bps, 2017).• Member of Medtronic Women’s Network Leadership Team. Created and launched Men Advocating Change for all male VPs at Medtronic. Medtronic won external Catalyst Award.

Oversaw worldwide revenue and profit in this $1.4B business. Separated business, created new management team, and initiated business operational processes. • Launched 2 new ICD product families worldwide including +40 point share gain in Japan.• Drove $240M acquisition, integration and management of TYRX, Inc. to launch infection control business. Deal economics achieved to date. Launched 7000 patient randomized clinical trial. Created Medtronic’s first outcomes-based risk share healthcare economics program.• Awards: Best Revenue Performance (2013), Best EBIT Performance (2013), Highest Share Growth (2013)

Led clinical research group with $280M budget and >200 ongoing clinical trials. Member of senior staff of $8B Group reporting to Group President.

Managed all clinical research and reimbursement activities in $5B CRDM Business. Clinical trial portfolio of >100 studies worldwide with budget >$100M. • Integrated 2 separate clinical organizations into single function. • Initiated and achieved 25% reduction over three years in cost of running clinical trials.

Created new business models based on physiologic information contained in medical devices.

Expatriate assignment directly responsible for P/L and all aspects of $300M CRDM and PhysioControl businesses in Japan. • Spearheaded turnaround achieving plan in 2nd year in all 4 major components: revenue, EBIT, inventory, and DSO. First time this had been achieved in >6 years.• Launched 21 new products (pacemakers, implantable and external defibrillators, heart failure devices), including one completely new therapy (cardiac resynchronization defibrillator). Created 20-center clinical trial to launch new therapy.• Created new Education and Training Center for all Medtronic Japan.

Member of Senior Staff of $5B business with responsibilities in government affairs, investor relations, public relations, and physician relations• CMS Medicare Coverage Advisory Committee member, Industry Representative (3 years).• Member of executive team that expanded Medicare coverage for ICDs (“SCD-HeFT indication”).• Led FDA panel presentations for new therapies and products.• Met extensively with investors/analysts independently as well as with CEO, CFO, and COO.• Product Development Program Leader (2002-5) of new platform and families of pacemakers, defibrillators and heart failure devices.• Additional functional management (2000-2): Reimbursement, Clinical, Research, Patents, Physician Relations

Cardiologist (Board certified: cardiac electrophysiology; cardiology; internal medicine). Authored 46 Papers, 20 Review Articles, 1 Book, 16 Book Chapters, 83 Abstracts.Editorial Board, Mayo Clinic Proceedings (1992-4)Director, Cardiovascular Fellows Training Program